TY - JOUR
T1 - Research response to coronavirus disease 2019 needed better coordination and collaboration
T2 - a living mapping of registered trials
AU - The COVID-NMA Consortium Team
AU - Nguyen, Van Thu
AU - Rivière, Philippe
AU - Ripoll, Pierre
AU - Barnier, Julien
AU - Vuillemot, Romain
AU - Ferrand, Gabriel
AU - Cohen-Boulakia, Sarah
AU - Ravaud, Philippe
AU - Boutron, Isabelle
AU - Alawadhi, Solaf
AU - Amer-Yahia, Sihem
AU - Ávila, Camila
AU - Bafeta, Aïda
AU - Baudry, Julia
AU - Bollig, Claudia
AU - Bonnet, Hillary
AU - Bouet, Marinette
AU - Cabanac, Guillaume
AU - Chaimani, Anna
AU - Chavalarias, David
AU - Chen, Yaolong
AU - Chevance, Astrid
AU - Coquery, Emmanuel
AU - Conil, Francoise
AU - Davidson, Mauricia
AU - De Nale, Laura
AU - Devane, Declan
AU - Diard, Elise
AU - Doreau, Bastien
AU - Evrenoglou, Theodoros
AU - Fabri, Alice
AU - Feron, Gilles
AU - Fezeu, Leopold
AU - Fouet, Mathilde
AU - El Chall, Lina Ghosn
AU - Graña, Carolina
AU - Grasselli, Giacomo
AU - Grolleau, François
AU - Hacid, Mohand Said
AU - Haddy, Loubna
AU - Hansen, Camilla
AU - Hohlfeld, Ameer
AU - Hróbjartsson, Asbjørn
AU - Julia, Chantal
AU - Mavridis, Dimitris
AU - Meerpohl, Joerg J.
AU - Meyer, Brice
AU - Naidoo, Nivantha
AU - Thu, Van Nguyen
AU - Oikonomidi, Theodora
AU - Pienaar, Elizabeth
AU - Quirke, Fiona
AU - Rada, Gabriel
AU - Riveros, Carolina
AU - Sauvant, Marie
AU - Schmucker, Christine
AU - Toumani, Farouk
AU - Tovey, David
AU - Xia, Jun
AU - Yu, Xuan
AU - Zoletic, Emina
AU - Zweigenbaum, Pierre
N1 - Publisher Copyright:
© 2020 The Author(s)
PY - 2021/2
Y1 - 2021/2
N2 - Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.
AB - Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.
KW - Clinical trial
KW - COVID-19
KW - Living mapping
KW - Meta-analysis
KW - Prevention
KW - Systematic review
KW - Treatment
UR - https://www.scopus.com/pages/publications/85096678173
U2 - 10.1016/j.jclinepi.2020.10.010
DO - 10.1016/j.jclinepi.2020.10.010
M3 - Article
C2 - 33096223
AN - SCOPUS:85096678173
SN - 0895-4356
VL - 130
SP - 107
EP - 116
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
ER -
SDG 3 Good Health and Well-being